Triple combination therapies for anti-aging
US-2024316086-A1 · Sep 26, 2024 · US
Sensitization of tumor cells to radiation therapy through administration of endothelin agonists
US8957014B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8957014-B2 |
| Application number | US-201313761043-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2013 |
| Priority date | Oct 24, 2002 |
| Publication date | Feb 17, 2015 |
| Grant date | Feb 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ET B agonist IRL1620.
First claim
Opening claim text (preview).
The invention claimed is: 1. A radiation combination therapy contributing to the treatment of a lymphoma in a patient in need thereof, the therapy comprising administering a first radiation sensitizing compound and a second radiation sensitizing compound to the patient, wherein administration of the first radiation sensitizing compound increases oxygenation of the lymphoma, thereby sensitizing the lymphoma to radiation-induced cellular damage, and wherein the first radiation sensi…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K41/0038Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8957014B2 cover?
- Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ET B agonist IRL1620.
- Who is the assignee on this patent?
- Univ Illinois, Spectrum Pharmaceuticals Inc, Trustees Of The University Of Illinoise Board Of
- What technology area does this patent fall under?
- Primary CPC classification A61K41/0038. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).